Penzberg, Germany and Madison, WI, USA, 28 May 2013
Roche launches new bead based DNA target enrichment reagent kit for Next Generation Sequencing
Roche today announced the global launch of its SeqCap EZ Pure Capture Bead Kit supporting target enrichment workflows prior to DNA sequencing. The newly introduced SeqCap EZ Pure Capture Bead Kit is designed to provide sensitive and robust methods for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results. With the addition of the new kit to its capture portfolio, Roche now offers SeqCap EZ Library probe pools and all target enrichment reagents in a one stop shop.
“This launch is another step in our continued and committed efforts to improve customer convenience and enhance the efficiency of genomics research based on our industry-leading target enrichment technology for next-generation sequencing,” said Thomas Schinecker, President Roche Sequencing Solutions.
Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels and custom designs. Roche also launched a suite of SeqCap EZ reagent kits in January this year for applications in single or multiplex target enrichment experiments. With the recent addition, the comprehensive set of capture reagents will allow a more streamlined target enrichment workflow and ensure superior sequence capture efficiency.
For more information about Roche NimbleGen, please visit www.nimblegen.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D.
The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN and SEQCAP are trademarks of Roche.